Will Kadcyla suffer the same fate as Zaltrap?
February 27 2013
The price of Kadcyla, the new targeted cancer drug from Roche/Genentech, leaves some analysts pondering its future.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.